Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Exclusion Criteria

• •1. Have primary central nervous system (CNS) lymphoma or secondary central nervous system (CNS) infiltration, transformed lymphoma, unclassified B-cell lymphoma with features intermediate between DLBCL and classical Hodgkin's lymphoma (HL), primary effusion lymphoma, plasma lymphoma;
• •2. Toxicity not yet recovered from previous anti-tumor therapies;
• •3. Uncontrolled systemic infections or infections requiring intravenous antibiotics;
• •4. Have received steroid hormone, chemotherapy, targeted therapy, radiotherapy, antibody-based therapies, within a specified amount of time per protocol;
• •5. Unable to swallow tablets, or presence of significant functional gastrointestinal disorders that may affect the intake, transport or absorption of the study drug;
• •6. Have received autologous stem cell transplant,or allogeneic stem cell transplant within a certain amount of time as specified in protocol;
• •7. Presence of active graft-versus-host reaction;
• •8. Have undergone a major surgery within the last month;
• •9. Evidence of possible human immunodeficiency virus (HIV) infection or hepatitis C virus (HCV) infection;
• •10. Have any cardiac impairment as defined per protocol;
• •11. Have prior history of malignancies other than diffuse large B-cell lymphoma (DLBCL).